Media Release
Zurich, November 25, 2014

The Swiss coronary stent company Qvanteq AG enrolled first patient in the QUEST I clinical study

Qvanteq AG today announced that it has enrolled the first patient in the First in Man (FiM) clinical study QUEST I, this is following earlier regulatory approval from the Dutch and Swiss authorities. The aim of the QUEST I study is to assess feasibility and safety of the ***Qstent***, a bioactive, coating-free coronary stent. The ***Qstent*** has shown excellent in-growth and low thrombogenicity in pre-clinical studies.

Earlier in the year, Qvanteq AG obtained the ISO 13485 certification.

“Enrolling the first patient is a significant step towards clinical proof of concept for our bioactive and coating-free coronary stent”, commented Qvanteq’s CEO and founder Arik Zucker. “It is also the result of several years of strong commitment to bringing our technology to patients”, he added.

“This unique stent concept is indeed very exciting because there is no drug coating and therefore, it might well present clear benefits for the treated patients in terms of minimum dual antiplatelet treatment time. Fast endothelialization accompanied by low restenotic and low thrombogenicity potential offers patients a very valuable alternative to currently used stents in the clinic”, says Prof. Patrick W. J. C. Serruys, Chairman of QUEST I at Erasmus University, Thoraxcentrum, Rotterdam, NL.

About QUEST I

Objective of this First in Man clinical study is to assess feasibility and safety of Qvanteq’s bioactive, coating-free coronary stent for treatment of stable coronary artery disease patients with de novo coronary artery stenosis. The study is a prospective, multicenter, open-label, single arm study; conducted in 4 cardiology centers in Switzerland and 2 in the Netherlands. In total, 35 patients will be enrolled. All patients will be treated with the ***Qstent***, Qvanteq’s bioactive coronary stent. Clinical follow-up is scheduled at 1, 6 & 12 months post-stent implantation. All patients will undergo angiography assessment (QCA) and high resolution intracoronary imaging using Optical Coherence Tomography investigation (OCT) at baseline and at 6 months follow-up. This will offer unique insights in the arterial healing profile of the ***Qstent***. Primary Angiographic endpoint is in-stent Late Lumen Loss at 6 months; assessed by QCA. Primary OCT endpoint is mean neointimal thickness at 6 months; assessed by OCT analysis.

About the *Qstent*

The ***Qstent*** is a novel and unique alternative to available coronary stents. It draws its neointimal suppression and low thrombogenicity entirely from its surface properties without

Qvanteq AG | Technoparkstrasse 1 | CH-8005 Zürich | phone +41 (0)44 500 98 90 | info@qvanteq.com

the need of coatings or eluting drugs. Neointimal suppression in combination with minimum time of dual anti-platelet treatment (DAPT) are in great demand and the ***Qstent*** might therefore offer advantages in the treatment of coronary artery disease patients.

The ***Qstent*** **bioactive** surface is ultra-hydrophilic and its unique surface selectively interacts with the blood: immediately upon introduction into the blood stream, ***Qstent's*** **bioactive** surface selectively recruits anti-thrombogenic and neointimal suppressive factors from the blood, leading to an optimal integration of the stent into the vessel wall.

Qvanteq's novel bioactive, coating-free surface technology is simple and cost effective and the surface of any stent can be modified accordingly.

About Qvanteq

Qvanteq AG develops novel bioactive, coating-free stents to address and overcome the clinically adverse effects of today's available stents. Qvanteq AG was founded in early 2009 and is held by private investors. Qvanteq is ISO 13485 certified. The company is based at the Technopark in Zurich, Switzerland.
Qvanteq is a spin-off company from the Swiss Federal Institute of Technology (ETH) Zurich. The company was awarded with the CTI start-up label in 2012.

For further enquiries, please contact:

Arik Zucker, CEO
info@qvanteq.com
www.qvanteq.com
+41 44 500 98 90